The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Samoilova E.M.

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Yusubalieva G.M.

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Belopasov V.V.

Astrakhan State Medical University

Ekusheva E.V.

Academy of Postgraduate Education under the Federal State Budgetary Unit «Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency»;
Belgorod State National Research University

Baklaushev V.P.

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Infections and inflammation in the development of stroke

Authors:

Samoilova E.M., Yusubalieva G.M., Belopasov V.V., Ekusheva E.V., Baklaushev V.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8‑2): 11‑21

DOI: 10.17116/jnevro202112108211

Views: 7040

Downloaded: 143

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Samoilova EM, Yusubalieva GM, Belopasov VV, Ekusheva EV, Baklaushev VP. Infections and inflammation in the development of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(8‑2):11‑21. (In Russ.)
https://doi.org/10.17116/jnevro202112108211

 
МСФ на ЯМ
Close metadata
Recommended articles:
Ischemic stroke in men 18—50 years of age. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):5-11
Features of apha­sic diso­rders in patients with acute cere­brovascular diso­rder in the posterior cere­bral artery basin. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):18-22
The rela­tionship between the deve­lopment of post-stroke cognitive impairment and changes in the coagulation component of hemo­stasis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):23-29
CT-predictors of unfa­vorable outcome in hemo­rrhagic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):37-41
The multidirectional effe­cts of thro­mbin and the possibility of their control in neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):42-48
Comparative characteristics of the effi­cacy and safety of the original alte­plase and its complete biosimilar in the treatment of ischemic stroke in real clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):49-54
Prevalence and risk factors of non-suicidal self-injury beha­vior. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):13-19
Trends in the inci­dence of mental and beha­vioral diso­rders during the COVID-19 pandemic in Penza Oblast. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):129-134
Advi­sability of caro­tid enda­rterectomy in asymptomatic patients. Piro­gov Russian Journal of Surgery. 2024;(3):45-53
Effe­ctiveness of body weight control using remote digi­tal technologies in various orga­nizational models of primary health care. Medi­cal Technologies. Asse­ssment and Choice. 2024;(1):26-36

The review systematizes data on the role of infectious diseases and systemic inflammation in the pathogenesis of stroke. Various risk factors for stroke associated with pro-inflammatory reactions and their contribution to the pathogenesis of cerebrovascular pathology are analyzed. The interaction of systemic inflammation with hemostasis disturbances and clots formation, activation of autoreactive clones of cytotoxic lymphocytes, the progression of endothelial damage, and other processes is shown. Along with infection, these factors increase the risk of stroke. The key mechanisms of the pathogenesis from the development of acute or chronic inflammation to the preconditions of stroke are presented. The mechanisms of the acting of the infectious process as a trigger factor and/or medium-term or long-term risk factors of stroke are described. A separate section is devoted to the mechanisms of developing cerebrovascular diseases after COVID-19. Identifying an increased risk of stroke due to infection can be of great preventive value. Understanding of this risk by specialists followed by correction of drug therapy and rehabilitation measures can reduce the incidence of cerebrovascular complications in infectious patients.

Keywords:

ischemic stroke
hemorrhagic stroke
infectious diseases
COVID-19
trigger risk factors
medium-term risk factors

Authors:

Samoilova E.M.

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Yusubalieva G.M.

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Belopasov V.V.

Astrakhan State Medical University

Ekusheva E.V.

Academy of Postgraduate Education under the Federal State Budgetary Unit «Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency»;
Belgorod State National Research University

Baklaushev V.P.

Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies of the Federal Medical and Biological Agency of Russia

Received:

17.05.2021

Accepted:

25.05.2021

List of references:

  1. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. Bull World Health Organ. 2016;94(9):634-634A. https://doi.org/10.2471/BLT.16.181636
  2. Thrift AG, Thayabaranathan T, Howard G, Howard VJ, Rothwell PM, Feigin VL, Norrving B, Donnan GA, Cadilhac DA. Global stroke statistics. Int J Stroke. 2017;12(1):13-32.  https://doi.org/10.1177/1747493016676285
  3. Boehme AK, Esenwa C, Elkind MS. Stroke Risk Factors, Genetics, and Prevention. Circ Res. 2017;120(3):472-495.  https://doi.org/10.1161/CIRCRESAHA.116.308398
  4. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D’Agostino RB, Larson MG, Kannel WB, Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049-1056. https://doi.org/10.1001/jama.290.8.1049
  5. Lumley T, Kronmal RA, Cushman M, Manolio TA, Goldstein S. A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol. 2002;55(2):129-136.  https://doi.org/10.1016/s0895-4356(01)00434-6
  6. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, Sung FC, Chen MF, Lee YT. Constructing the prediction model for the risk of stroke in a Chinese population: report from a cohort study in Taiwan. Stroke. 2010;41(9):1858-1864. https://doi.org/10.1161/STROKEAHA.110.586222
  7. Elkind MS. Why now? Moving from stroke risk factors to stroke triggers. Curr Opin Neurol. 2007;20(1):51-57.  https://doi.org/10.1097/WCO.0b013e328012da75
  8. Elkind MS, Carty CL, O’Meara ES, Lumley T, Lefkowitz D, Kronmal RA, Longstreth WT Jr. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke. 2011;42(7):1851-1856.
  9. Clar C, Oseni Z, Flowers N, Keshtkar-Jahromi M, Rees K. Influenza vaccines for preventing cardiovascular disease. Cochrane Database Syst Rev. 2015;(5):CD005050. Published 2015 May 5.  https://doi.org/10.1002/14651858.CD005050.pub3
  10. Walkey AJ, Hammill BG, Curtis LH, Benjamin E.J. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest. 2014;146(5):1187-1195. https://doi.org/10.1378/chest.14-0003
  11. Ross R, Glomset JA. The pathogenesis of atherosclerosis (first of two parts). N Engl J Med. 1976;295(7):369-377.  https://doi.org/10.1056/NEJM197608122950707
  12. Ross R, Glomset JA. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med. 1976;295(8):420-425.  https://doi.org/10.1056/NEJM197608192950805
  13. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans [published correction appears in Immunity. 2013;39(2):413]. Immunity. 2013;38(6):1092-1104. https://doi.org/10.1016/j.immuni.2013.06.009
  14. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6(2):131-138.  https://doi.org/10.1161/01.atv.6.2.131
  15. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969-979.  https://doi.org/10.1161/ATVBAHA.110.207415
  16. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol. 2008;48:171-197.  https://doi.org/10.1146/annurev.pharmtox.48.121806.154841
  17. De Caterina R, D’Ugo E, Libby P. Inflammation and thrombosis — testing the hypothesis with anti-inflammatory drug trials. Thromb Haemost. 2016;116(6):1012-1021. https://doi.org/10.1160/TH16-03-0246
  18. Chaulin AM, Duplyakov DV. Biomarkers of Acute Myocardial Infarction: Diagnostic and Prognostic Value. Part 2. Journal of Clinical Practice. 2020;11(3):75-84 (In Russ.). https://doi.org/10.17816/clinpract48893
  19. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709):132-140.  https://doi.org/10.1016/S0140-6736(09)61717-7
  20. Zhou Y, Han W, Gong D, Man C, Fan Y. Hs-CRP in stroke: A meta-analysis. Clin Chim Acta. 2016;453:21-27.  https://doi.org/10.1016/j.cca.2015.11.027
  21. Wang L, Li Y, Wang C, Guo W, Liu M. C-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review. Curr Neurovasc Res. 2019;16(5):405-415.  https://doi.org/10.2174/1567202616666191026122011
  22. Jillella DV, Wisco DR. Infectious causes of stroke. Curr Opin Infect Dis. 2019;32(3):285-292.  https://doi.org/10.1097/QCO.0000000000000547
  23. Parikh NS, Merkler AE, Iadecola C. Inflammation, Autoimmunity, Infection, and Stroke: Epidemiology and Lessons From Therapeutic Intervention. Stroke. 2020;51(3):711-718.  https://doi.org/10.1161/STROKEAHA.119.024157
  24. Malone K, Amu S, Moore AC, Waeber C. The immune system and stroke: from current targets to future therapy. Immunol Cell Biol. 2019;97(1):5-16.  https://doi.org/10.1111/imcb.12191
  25. Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V, Hasan AA, Amar S. Inflammation, Immunity, and Infection in Atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2018;72(17):2071-2081. https://doi.org/10.1016/j.jacc.2018.08.1043
  26. Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol. 2010;67(1):33-38.  https://doi.org/10.1001/archneurol.2009.271
  27. Aarabi G, Heydecke G, Seedorf U. Roles of Oral Infections in the Pathomechanism of Atherosclerosis. Int J Mol Sci. 2018;19(7):1978. Published 2018 Jul 6.  https://doi.org/10.3390/ijms19071978
  28. Aarabi G, Thomalla G, Heydecke G, Seedorf U. Chronic oral infection: An emerging risk factor of cerebral small vessel disease. Oral Dis. 2019;25(3):710-719.  https://doi.org/10.1111/odi.12912
  29. Ovbiagele B, Nath A. Increasing incidence of ischemic stroke in patients with HIV infection. Neurology. 2011;76(5):444-450.  https://doi.org/10.1212/WNL.0b013e31820a0cfc
  30. Chow FC, He W, Bacchetti P, Regan S, Feske SK, Meigs JB, Grinspoon SK, Triant VA. Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort. Neurology. 2014;83(19):1705-1711. https://doi.org/10.1212/WNL.0000000000000958
  31. Gutierrez J, Goldman J, Dwork AJ, Elkind MS, Marshall RS, Morgello S. Brain arterial remodeling contribution to nonembolic brain infarcts in patients with HIV. Neurology. 2015;85(13):1139-1145. https://doi.org/10.1212/WNL.0000000000001976
  32. Gutierrez J, Elkind MS, Marshall RS. Cardiovascular profile and events of US adults 20—49 years with HIV: results from the NHANES 1999—2008. AIDS Care. 2013;25(11):1385-1391. https://doi.org/10.1080/09540121.2013.769493
  33. Shao IY, Elkind MSV, Boehme AK. Risk Factors for Stroke in Patients With Sepsis and Bloodstream Infections. Stroke. 2019;50(5):1046-1051. https://doi.org/10.1161/STROKEAHA.118.023443
  34. Sebastian S, Stein LK, Dhamoon MS. Infection as a Stroke Trigger. Stroke. 2019;50(8):2216-2218. https://doi.org/10.1161/STROKEAHA.119.025872
  35. Warren-Gash C, Blackburn R, Whitaker H, McMenamin J, Hayward AC. Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland. Eur Respir J. 2018;51(3):1701794. Published 2018 Mar 29.  https://doi.org/10.1183/13993003.01794-2017
  36. Astrup LB, Skovgaard K, Rasmussen RS, Iburg TM, Agerholm JS, Aalbæk B, Jensen HE, Nielsen OL, Johansen FF, Heegaard PMH, Leifsson PS. Staphylococcus aureus infected embolic stroke upregulates Orm1 and Cxcl2 in a rat model of septic stroke pathology. Neurol Res. 2019;41(5):399-412.  https://doi.org/10.1080/01616412.2019.1573455
  37. Fernandes BFS, Caramelli P. Ischemic stroke and infectious diseases in low-income and middle-income countries. Curr Opin Neurol. 2019;32(1):43-48.  https://doi.org/10.1097/WCO.0000000000000641
  38. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004;351(25):2611-2618. https://doi.org/10.1056/NEJMoa041747
  39. Müller S, Wang H, Silverman GJ, Bramlet G, Haigwood N, Köhler H. B-cell abnormalities in AIDS: stable and clonally-restricted antibody response in HIV-1 infection. Scand J Immunol. 1993;38(4):327-334.  https://doi.org/10.1111/j.1365-3083.1993.tb01734.x
  40. Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34(14):1643-1647. https://doi.org/10.1016/j.vaccine.2016.02.004
  41. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, Savarino S, Zambrano B, Moureau A, Khromava A, Moodie Z, Westling T, Mascareñas C, Frago C, Cortés M, Chansinghakul D, Noriega F, Bouckenooghe A, Chen J, Ng SP, Gilbert PB, Gurunathan S, DiazGranados CA. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy. N Engl J Med. 2018;379(4):327-340.  https://doi.org/10.1056/NEJMoa1800820
  42. Gould EA, Buckley A. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol. 1989;70(Pt 6):1605-1608. https://doi.org/10.1099/0022-1317-70-6-1605
  43. Bröker M, Kollaritsch H. After a tick bite in a tick-borne encephalitis virus endemic area: current positions about post-exposure treatment. Vaccine. 2008;26(7):863-868.  https://doi.org/10.1016/j.vaccine.2007.11.046
  44. Sato R, Hamada N, Kashiwagi T, Imamura Y, Hara K, Nishimura M, Kamimura T, Takasaki T, Watanabe H, Koga T. Dengue Hemorrhagic Fever in a Japanese Traveler with Pre-existing Japanese Encephalitis Virus Antibody. Trop Med Health. 2015;43(2):85-88.  https://doi.org/10.2149/tmh.2014-34
  45. Takada A, Watanabe S, Okazaki K, Kida H, Kawaoka Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J Virol. 2001;75(5):2324-2330. https://doi.org/10.1128/JVI.75.5.2324-2330.2001
  46. Nakayama E, Tomabechi D, Matsuno K, Kishida N, Yoshida R, Feldmann H, Takada A. Antibody-dependent enhancement of Marburg virus infection. J Infect Dis. 2011;204(suppl 3):978-985.  https://doi.org/10.1093/infdis/jir334
  47. Meyer K, Ait-Goughoulte M, Keck ZY, Foung S, Ray R. Antibody-dependent enhancement of hepatitis C virus infection. J Virol. 2008;82(5):2140-2149. https://doi.org/10.1128/JVI.01867-07
  48. Thomas HI, Wilson S, O’Toole CM, Lister CM, Saeed AM, Watkins RP, Morgan-Capner P. Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin Exp Immunol. 1996;103(2):185-191.  https://doi.org/10.1046/j.1365-2249.1996.951642.x
  49. Руководство по проведению клинических исследований лекарственных средств (иммунобиологические лекарственные препараты). Часть вторая. Под ред. Миронова А.Н. М.: Гриф и К; 2012.
  50. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, He L, Chen Y, Wu J, Shi Z, Zhou Y, Du L, Li F. Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. J Virol. 2020;94(5):e02015-19. Published 2020 Feb 14.  https://doi.org/10.1128/JVI.02015-19
  51. Karmarkar MG, Hule GP, Cameron A, Mehta PR, Khopkar U, Hase NK, Sriprakash KS. Antibodies to group A streptococcal virulence factors, SIC and DRS, increase predilection to GAS pyoderma. BMC Infect Dis. 2015;15:113. Published 2015 Mar 3.  https://doi.org/10.1186/s12879-015-0857-4
  52. Maglione PJ, Xu J, Casadevall A, Chan J. Fc gamma receptors regulate immune activation and susceptibility during Mycobacterium tuberculosis infection. J Immunol. 2008;180(5):3329-3338. https://doi.org/10.4049/jimmunol.180.5.3329
  53. Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front Immunol. 2012;3:334. Published 2012 Nov 8.  https://doi.org/10.3389/fimmu.2012.00334
  54. Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, Sardesai NY, Muthumani K, Weiner DB. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep. 2015;5:12616. Published 2015 Jul 29.  https://doi.org/10.1038/srep12616
  55. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, Newman A, Loehr L, Folsom AR, Elkind MS, Lyles MF, Kronmal RA, Yende S. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-274.  https://doi.org/10.1001/jama.2014.18229
  56. Dalager-Pedersen M, Søgaard M, Schønheyder HC, Nielsen H, Thomsen RW. Risk for myocardial infarction and stroke after community-acquired bacteremia: a 20-year population-based cohort study. Circulation. 2014;129(13):1387-1396. https://doi.org/10.1161/CIRCULATIONAHA.113.006699
  57. Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol. 2011;40(3):819-827.  https://doi.org/10.1093/ije/dyr012
  58. Chen C, Ai QD, Chu SF, Zhang Z, Chen NH. NK cells in cerebral ischemia. Biomed Pharmacother. 2019;109:547-554.  https://doi.org/10.1016/j.biopha.2018.10.103
  59. Krishnan S, Lawrence CB. Old Dog New Tricks; Revisiting How Stroke Modulates the Systemic Immune Landscape. Front Neurol. 2019;10:718. Published 2019 Jul 2.  https://doi.org/10.3389/fneur.2019.00718
  60. Rocha EA, Topcuoglu MA, Singhal AB. Post-stroke Recrudescence from Infection: an Immunologic Mechanism? Transl Stroke Res. 2019;10(2):146-149.  https://doi.org/10.1007/s12975-018-0651-x
  61. Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci. 2011;300(1 2):97-102.  https://doi.org/10.1016/j.jns.2010.09.023
  62. Belopasov VV, Yachou Y, Samoilova EM, Baklaushev VP. The Nervous System Damage in COVID-19. Journal of Clinical Practice. 2020;11(2): In Press. (In Russ.). https://doi.org/10.17816/clinpract34851
  63. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, van der Meer F, Kallio K, Kaya T, Anastasina M, Smura T, Levanov L, Szirovicza L, Tobi A, Kallio-Kokko H, Österlund P, Joensuu M, Meunier FA, Butcher SJ, Winkler MS, Mollenhauer B, Helenius A, Gokce O, Teesalu T, Hepojoki J, Vapalahti O, Stadelmann C, Balistreri G, Simons M. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370(6518):856-860.  https://doi.org/10.1126/science.abd2985
  64. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020;77:8-12.  https://doi.org/10.1016/j.jocn.2020.05.017
  65. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. https://doi.org/10.1016/S0140-6736(20)30628-0
  66. Tveito K. Cytokine storms in COVID-19 cases? Cytokinstormer ved covid-19? Tidsskr Nor Laegeforen. 2020;140:10.4045/tidsskr.20.0239. Published 2020 Mar 23.  https://doi.org/10.4045/tidsskr.20.0239
  67. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.  https://doi.org/10.1016/j.thromres.2020.04.013
  68. Li Y, Li M, Wang M, Zhou Y, Chang J, Xian Y, Wang D, Mao L, Jin H, Hu B. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. Stroke Vasc Neurol. 2020;5(3):279-284.  https://doi.org/10.1136/svn-2020-000431
  69. Radmanesh A, Raz E, Zan E, Derman A, Kaminetzky M. Brain Imaging Use and Findings in COVID-19: A Single Academic Center Experience in the Epicenter of Disease in the United States. AJNR Am J Neuroradiol. 2020;41(7):1179-1183. https://doi.org/10.3174/ajnr.A6610
  70. Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S, Lewis A, Melmed K, Hochman K, Horwitz L, Galetta S, Berger J. Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis. 2020;29(8):104984. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104984
  71. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Li Y, Hu B. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690.  https://doi.org/10.1001/jamaneurol.2020.1127
  72. Favas TT, Dev P, Chaurasia RN, Chakravarty K, Mishra R, Joshi D, Mishra VN, Kumar A, Singh VK, Pandey M, Pathak A. Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions. Neurol Sci. 2020;41(12):3437-3470. https://doi.org/10.1007/s10072-020-04801-y
  73. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7(1):23-38.  https://doi.org/10.1186/cc1854
  74. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114(12):2367-2374. https://doi.org/10.1182/blood-2009-05-199208
  75. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340(2):115-126.  https://doi.org/10.1056/NEJM199901143400207
  76. Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993;82(2):513-520. 
  77. Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, Fay WP. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance. Arterioscler Thromb Vasc Biol. 2008;28(4):698-704.  https://doi.org/10.1161/ATVBAHA.107.160903
  78. Levine DA, Langa KM, Rogers MA. Acute infection contributes to racial disparities in stroke mortality. Neurology. 2014;82(11):914-921.  https://doi.org/10.1212/WNL.0000000000000214
  79. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4):372. Published 2020 Mar 27.  https://doi.org/10.3390/v12040372
  80. Supotnitskiy MV. Novel coronavirus SARS-CoV-2 in the context of global epidemiology of coronavirus infections. Journal of NBC Protection Corps. 2019;4(1):32-65. (In Russ.). https://doi.org/10.35825/2587-5728-2020-4-1-32-65
  81. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Hafner G, Pfeifer U, Meyer J. Are morphological or functional changes in the carotid artery wall associated with Chlamydia pneumoniae, Helicobacter pylori, cytomegalovirus, or herpes simplex virus infection? Stroke. 2000;31(9):2127-2133. https://doi.org/10.1161/01.str.31.9.2127
  82. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in communities (ARIC) study. Arch Intern Med. 2000;160(13):2027-2032. https://doi.org/10.1001/archinte.160.13.2027
  83. Kalayoglu MV, Libby P, Byrne GI. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA. 2002;288(21):2724-2731. https://doi.org/10.1001/jama.288.21.2724
  84. Eisenhardt SU, Habersberger J, Murphy A, Chen YC, Woollard KJ, Bassler N, Qian H, von Zur Muhlen C, Hagemeyer CE, Ahrens I, Chin-Dusting J, Bobik A, Peter K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circ Res. 2009;105(2):128-137.  https://doi.org/10.1161/CIRCRESAHA.108.190611
  85. Pepys MB, Hirschfield GM. C-reactive protein and atherothrombosis. Ital Heart J. 2001;2(3):196-199. 
  86. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045-2051. https://doi.org/10.1161/ATVBAHA.108.179705
  87. Rifai N. High-sensitivity C-reactive protein: a useful marker for cardiovascular disease risk prediction and the metabolic syndrome. Clin Chem. 2005;51(3):504-505.  https://doi.org/10.1373/clinchem.2004.044990
  88. Curb JD, Abbott RD, Rodriguez BL, Sakkinen P, Popper JS, Yano K, Tracy RP. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation. 2003;107(15):2016-2020. https://doi.org/10.1161/01.CIR.0000065228.20100.F7
  89. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112(6):900-905.  https://doi.org/10.1161/CIRCULATIONAHA.104.506337
  90. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359(18):1897-1908. https://doi.org/10.1056/NEJMoa0707402
  91. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI. Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health Study. Am J Hum Genet. 2008;82(5):1185-1192. https://doi.org/10.1016/j.ajhg.2008.03.015
  92. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb Haemost. 2009;102(2):215-222.  https://doi.org/10.1160/TH09-05-0297
  93. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jørgensen T, Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-589.  https://doi.org/10.1093/eurheartj/eht367
  94. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y, Lowe GD. The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. Atherosclerosis. 2010;209(2):551-557.  https://doi.org/10.1016/j.atherosclerosis.2009.09.030
  95. Baklaushev VP, Kulemzin SV, Gorchakov AA, Lesnyak VN, Ysubalieva GM, Sotnikova AG. COVID-19. Etiology, Pathogenesis, Diagnosis and Treatment. Journal of Clinical Practice. 2020;11(1):7-20. (In Russ.). https://doi.org/10.17816/clinpract26339
  96. Reddy KJ, Singh M, Batsell RR, Bangit JR, Miraskar RA, Zaheer MS. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy. Prev Cardiol. 2010;13(3):130-134.  https://doi.org/10.1111/j.1751-7141.2009.00060.x
  97. Koutouzis T, Haber D, Shaddox L, Aukhil I, Wallet SM. Autoreactivity of serum immunoglobulin to periodontal tissue components: a pilot study. J Periodontol. 2009;80(4):625-633.  https://doi.org/10.1902/jop.2009.080422
  98. Morimoto RI. Cells in stress: transcriptional activation of heat shock genes. Science. 1993;259(5100):1409-1410. https://doi.org/10.1126/science.8451637
  99. Siqueira JF Jr, Rôças IN. Bacterial pathogenesis and mediators in apical periodontitis. Braz Dent J. 2007;18(4):267-280.  https://doi.org/10.1590/s0103-64402007000400001
  100. Goulhen F, Grenier D, Mayrand D. Oral microbial heat-shock proteins and their potential contributions to infections. Crit Rev Oral Biol Med. 2003;14(6):399-412.  https://doi.org/10.1177/154411130301400603
  101. Ford PJ, Gemmell E, Hamlet SM, Hasan A, Walker PJ, West MJ, Cullinan MP, Seymour GJ. Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol Immunol. 2005;20(5):296-302.  https://doi.org/10.1111/j.1399-302X.2005.00230.x
  102. Root-Bernstein R, Fairweather D. Complexities in the relationship between infection and autoimmunity. Curr Allergy Asthma Rep. 2014;14(1):407.  https://doi.org/10.1007/s11882-013-0407-3
  103. Myers JM, Fairweather D, Huber SA, Cunningham MW. Autoimmune myocarditis, valvulitis, and cardiomyopathy. Curr Protoc Immunol. 2013;Chapter 15:Unit-15.14.51.  https://doi.org/10.1002/0471142735.im1514s101
  104. Owens GP, Bennett JL. Trigger, pathogen, or bystander: the complex nexus linking Epstein—Barr virus and multiple sclerosis. Mult Scler. 2012;18(9):1204-1208. https://doi.org/10.1177/1352458512448109
  105. Zhang P, Cox CJ, Alvarez KM, Cunningham MW. Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol. 2009;183(1):27-31.  https://doi.org/10.4049/jimmunol.0800861
  106. Yang C, Hawkins KE, Doré S, Candelario-Jalil E. Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke. Am J Physiol Cell Physiol. 2019;316(2):135-153.  https://doi.org/10.1152/ajpcell.00136.2018
  107. Abdullahi W, Tripathi D, Ronaldson PT. Blood-brain barrier dysfunction in ischemic stroke: targeting tight junctions and transporters for vascular protection. Am J Physiol Cell Physiol. 2018;315(3):343-356.  https://doi.org/10.1152/ajpcell.00095.2018
  108. Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Am Nat. 1964;98:129-149. 
  109. Zabriskie JB, Freimer EH. An immunological relationship between the group. A streptococcus and mammalian muscle. J Exp Med. 1966;124:661-678. 
  110. Fujinami RS, Oldstone MB, Wroblewska Z, Frankel ME, Koprowski H. Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci USA. 1983;80(8):2346-2350. https://doi.org/10.1073/pnas.80.8.2346
  111. Cunningham MW. Streptococcus and rheumatic fever. Curr Opin Rheumatol. 2012;24(4):408-416.  https://doi.org/10.1097/BOR.0b013e32835461d3
  112. Massilamany C, Gangaplara A, Steffen D, Reddy J. Identification of novel mimicry epitopes for cardiac myosin heavy chain-α that induce autoimmune myocarditis in A/J mice. Cell Immunol. 2011;271(2):438-449.  https://doi.org/10.1016/j.cellimm.2011.08.013
  113. Christen U, Bender C, von Herrath MG. Infection as a cause of type 1 diabetes? Curr Opin Rheumatol. 2012;24(4):417-423.  https://doi.org/10.1097/BOR.0b013e3283533719
  114. Trost B, Lucchese G, Stufano A, Bickis M, Kusalik A, Kanduc D. No human protein is exempt from bacterial motifs, not even one. Self Nonself. 2010;1(4):328-334.  https://doi.org/10.4161/self.1.4.13315
  115. Kanduc D. Quantifying the possible cross-reactivity risk of an HPV16 vaccine. J Exp Ther Oncol. 2009;8(1):65-76. 
  116. Rodríguez Y, Rojas M, Pacheco Y, et al. Guillain-Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. 2018;15(6):547-562.  https://doi.org/10.1038/cmi.2017.142
  117. Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42(1):102-111.  https://doi.org/10.1007/s12016-011-8294-7
  118. Sarukhan A, Garcia C, Lanoue A, von Boehmer H. Allelic inclusion of T cell receptor alpha genes poses an autoimmune hazard due to low-level expression of autospecific receptors. Immunity. 1998;8(5):563-570.  https://doi.org/10.1016/s1074-7613(00)80561-0
  119. Rojas M, Restrepo-Jiménez P, Monsalve DM, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Leung PSC, Ansari AA, Gershwin ME, Anaya JM. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100-123.  https://doi.org/10.1016/j.jaut.2018.10.012
  120. Wakabayashi K, Lian ZX, Leung PS, Moritoki Y, Tsuneyama K, Kurth MJ, Lam KS, Yoshida K, Yang GX, Hibi T, Ansari AA, Ridgway WM, Coppel RL, Mackay IR, Gershwin ME. Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology. 2008;48(2):531-540.  https://doi.org/10.1002/hep.22390
  121. Blank M, Barzilai O, Shoenfeld Y. Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol. 2007;32(1):111-118.  https://doi.org/10.1007/BF02686087
  122. Lucchese G, Flöel A, Stahl B. Cross-Reactivity as a Mechanism Linking Infections to Stroke. Front Neurol. 2019;10:469. Published 2019 May 14.  https://doi.org/10.3389/fneur.2019.00469
  123. Achar A, Ghosh C. COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance. Cells. 2020;9(11):2360. Published 2020 Oct 27.  https://doi.org/10.3390/cells9112360

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.